Canadian Helicobacter Study Group Consensus Conference: Update on the management of Helicobacter pylori--an evidence-based evaluation of six topics relevant to clinical outcomes in patients evaluated for H pylori infection
about
sameAs
Optimum duration of regimens for Helicobacter pylori eradicationOptimum duration of regimens for Helicobacter pylori eradicationSequential versus standard triple first-line therapy forHelicobacter pylorieradicationUpdate on diagnostic value of breath test in gastrointestinal and liver diseasesCarbon-13 urea breath test for Helicobacter pylori infection in patients with uninvestigated ulcer-like dyspepsia: an evidence-based analysisCost-effectiveness of the carbon-13 urea breath test for the detection of Helicobacter pylori: an economic analysisPrevention and treatment of NSAID-induced gastroduodenal injuryShort-term triple therapy with azithromycin for Helicobacter pylori eradication: low cost, high compliance, but low efficacyStandard triple, bismuth pectin quadruple and sequential therapies for Helicobacter pylori eradicationSeven-day quintuple regimen as a rescue therapy for Helicobacter pylori eradicationEmpiric therapies for Helicobacter pylori infections.Antimicrobial susceptibility of Canadian isolates of Helicobacter pylori in Northeastern Ontario.Pharmacological regimens for eradication of Helicobacter pylori: an overview of systematic reviews and network meta-analysis.A screening program to test and treat for Helicobacter pylori infection: Cost-utility analysis by age, sex and ethnicity.Helicobacter pylori infection: treatment options.Stool antigen tests in the diagnosis of Helicobacter pylori infection before and after eradication therapyPrevalence of Helicobacter pylori in a First Nations population in northwestern OntarioA meta-analysis of the success rate of Helicobacter pylori therapy in Canada.Helicobacter pylori eradication with either 7-day or 10-day triple therapies, and with a 10-day sequential regimen.Effectiveness of Second through Sixth Line Salvage Helicobacter pylori Treatment: Bismuth Quadruple Therapy is Almost Always a Reasonable Choice.Gastric Cancer Consensus conference recommends Helicobacter pylori screening and treatment in asymptomatic persons from high-risk populations to prevent gastric cancer.Helicobacter pylori infection in Canadian and related Arctic Aboriginal populations.13C urea breath test for (Helicobacter pylori): determination of the optimal cut-off point in a Canadian community population.13C urea breath test for (Helicobacter pylori): evaluation of 10-minute breath collection.Canadian Association of Gastroenterology Clinical Practice Guidelines: The use of tumour necrosis factor-alpha antagonist therapy in Crohn's disease.Helicobacter pylori Eradication Therapy in Nonulcer Dyspepsia is Beneficial.Helicobacter pylori status among patients undergoing gastroscopy in rural northern Alberta.Treatment of Helicobacter pylori in surgical practice: a randomised trial of triple versus quadruple therapy in a rural district general hospital.Adherence and barriers to H. pylori treatment in Arctic Canada.Disease manifestations of Helicobacter pylori infection in Arctic Canada: using epidemiology to address community concerns.A randomized controlled trial comparing sequential with triple therapy for Helicobacter pylori in an Aboriginal community in the Canadian NorthSecond Asia-Pacific Consensus Guidelines for Helicobacter pylori infection.Prevention of NSAID-related upper gastrointestinal toxicity: a meta-analysis of traditional NSAIDs with gastroprotection and COX-2 inhibitors.Guidelines for the diagnosis and treatment of Helicobacter pylori infection in Korea, 2013 revised edition.Meta-analysis: proton pump inhibitor use and the risk of community-acquired pneumonia.Is quadruple therapy the new triple therapy for H pylori?Effective and safe proton pump inhibitor therapy in acid-related diseases - A position paper addressing benefits and potential harms of acid suppressionHelicobacter pylori and immigrant health.Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies.Helicobacter pylori management in non-steroidal anti-inflammatory drug therapy patients in primary care.
P2860
Q24201841-0422DACB-9212-4EA8-8746-4311330D093DQ24241402-D046D702-0915-4544-92D6-EDFB4AF88522Q26471410-F0A5C2AE-99E5-4F8C-B59A-BC90E0DA7D0EQ26738290-95A1C60F-3E25-4956-B8AE-A1BA8B3632A1Q26860922-2E167612-035D-4855-8C4E-2472D350734CQ27024794-1DD67AB2-926B-44C6-822D-4B7B1E53E6E0Q28195728-E348F5E3-5986-4B28-BDA4-E9C8CA279E00Q33338688-CCCF7982-0CB4-4D7B-BFD6-1B937697A415Q34117880-E3EA605D-353F-49DB-B5AD-A505C98AC48AQ34932701-921A5D38-701A-43C9-84DF-6D7CD35BB8D2Q35045027-1B461D9D-F762-4BA3-8BFB-AD3EE0B2F778Q35867229-E309F021-F496-4BC9-A7D7-9B91ED4B02A3Q36086382-3167BEDF-05B2-412B-B558-643E63249DBEQ36285479-69D15E65-4EE6-48D6-89AD-7716AF20A417Q36404967-1A15AF92-D9E2-47B7-A3BC-C247701B96D8Q36497047-D900979B-618A-481A-90FA-BCE54D922FF6Q36762101-2C4992DF-D95B-436A-994A-2B2D589E6699Q36823731-7ABE81B5-EB15-47F7-9A15-8B9A6F420047Q36883328-64DB0E00-4F92-4F34-BEEC-78A91AC2880CQ36997005-39409C4A-0553-4554-BFBE-EE4A1BBA06B6Q37110280-1A1F6132-26C2-44B1-B90C-4C502C950177Q37114662-D3D9A0CE-1AE5-4399-B87D-E21B75768AF3Q37140251-2185B571-C2D0-4538-8ACD-4469C9183E29Q37140256-30C2D2E6-9CAE-4395-B40E-0C525A50859FQ37223169-C2260098-C582-45B6-802B-6D77347DE96EQ37243559-A87DE91C-06A2-4CED-8861-EDD67932877AQ37256148-F972E934-18C6-48C1-8B42-8D25026435B4Q37290815-3BB471A4-3793-4DF9-8A00-50337C56D76EQ37459957-D5DA2C3E-21EE-48F7-B8DF-06E7B87540FAQ37516556-92B587AF-0F14-47F5-92A3-7AF6A82F3B7DQ37558559-5BCD8FB2-4801-4347-B7E5-F568FA855C31Q37605214-F636A53A-3DE5-4CA6-9C19-AFEC458D4C37Q37893966-1C57124F-4680-4569-8489-3F41D98631AFQ38206548-30DAB2E5-2A15-4CD2-B5B1-A00DF4184B30Q39892787-E2F178C7-F223-4C23-BE0A-4A01D290944FQ40594944-46C31912-5901-4E65-AC8A-5EDEF608F3D1Q42371575-7BDA1BF8-5053-456C-AE11-46BCCE8637B8Q43052474-20AF9A6B-1084-4131-A32A-BBDED471951BQ45166033-BFD6CBA0-2134-495E-86AB-6F5903999466Q45899590-CA392394-3240-4496-BBD3-8AFB8A99841E
P2860
Canadian Helicobacter Study Group Consensus Conference: Update on the management of Helicobacter pylori--an evidence-based evaluation of six topics relevant to clinical outcomes in patients evaluated for H pylori infection
description
2004 nî lūn-bûn
@nan
2004 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Canadian Helicobacter Study Gr ...... aluated for H pylori infection
@ast
Canadian Helicobacter Study Gr ...... aluated for H pylori infection
@en
Canadian Helicobacter Study Gr ...... aluated for H pylori infection
@nl
type
label
Canadian Helicobacter Study Gr ...... aluated for H pylori infection
@ast
Canadian Helicobacter Study Gr ...... aluated for H pylori infection
@en
Canadian Helicobacter Study Gr ...... aluated for H pylori infection
@nl
prefLabel
Canadian Helicobacter Study Gr ...... aluated for H pylori infection
@ast
Canadian Helicobacter Study Gr ...... aluated for H pylori infection
@en
Canadian Helicobacter Study Gr ...... aluated for H pylori infection
@nl
P2093
P3181
P356
P1476
Canadian Helicobacter Study Gr ...... aluated for H pylori infection
@en
P2093
Alan Thomson
Carlo Fallone
Fiona Smaill
Nigel Flook
Phil Sherman
Richard Hunt
Sander Veldhuyzan van Zanten
P304
P3181
P356
10.1155/2004/326767
P407
P577
2004-09-01T00:00:00Z